Antisoma goes back to basics following Phase III failure
This article was originally published in Scrip
Antisoma is stopping all clinical development activity and is severely downsizing operations following the failure in Phase III of its lead programme, AS1413, a topoisomerase II inhibitor, in secondary acute myeloid leukaemia (AML). The trial failed to meet the primary endpoint and development of AS1413 will be discontinued.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.